Targeting PI3K signalling in cancer: opportunities, challenges and limitations (original) (raw)

• Katso, R. et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615–675 (2001).
  Article CAS PubMed Google Scholar
• Zhao, L. & Vogt, P. K. Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486–5496 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606–619 (2006).
  Article CAS PubMed Google Scholar
• Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403–414 (2008).
  Article CAS PubMed Google Scholar
• Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497–5510 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, J., Manning, B. D. & Cantley, L. C. Targeting the PI3K–Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257–262 (2003).
  Article CAS PubMed Google Scholar
• Garcia-Echeverria, C. & Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511–5526 (2008).
  Article CAS PubMed Google Scholar
• Qiu, Y. & Kung, H. J. Signaling network of the Btk family kinases. Oncogene 19, 5651–5661 (2000).
  Article CAS PubMed Google Scholar
• Cain, R. J. & Ridley, A. J. Phosphoinositide 3-kinases in cell migration. Biol. Cell 101, 13–29 (2009).
  Article CAS PubMed Google Scholar
• Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L. & Roberts, T. M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315, 239–242 (1985). This study showed that the polyomavirus middle T antigen requires a physical interaction with PI3K to transform cells.
  Article CAS PubMed Google Scholar
• Songyang, Z. et al. SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767–778 (1993).
  Article CAS PubMed Google Scholar
• Engelman, J. A. et al. ErbB3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 102, 3788–3793 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bianco, R. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812–2822 (2003).
  Article CAS PubMed Google Scholar
• Moulder, S. L. et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887–8895 (2001).
  CAS PubMed Google Scholar
• Yakes, F. M. et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132–4141 (2002).
  CAS PubMed Google Scholar
• Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
  Article CAS PubMed Google Scholar
• Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395–402 (2007). This study showed that breast cancers with amplifications of ERBB2 treated with trastuzumab have a worse prognosis if they also harbour PIK3CA mutations or have lost PTEN expression.
  Article CAS PubMed Google Scholar
• Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287–290 (2007).
  Article CAS PubMed Google Scholar
• Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
  Article CAS PubMed Google Scholar
• Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609–2619 (2008).
  CAS PubMed PubMed Central Google Scholar
• Rodriguez-Viciana, P. et al. Phosphatidylinositol3-OH- kinase as a direct target of Ras. Nature 370, 527–532 (1994).
  Article CAS PubMed Google Scholar
• Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase g. Cell 103, 931–943 (2000).
  Article CAS PubMed Google Scholar
• Kurosu, H. et al. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110b is synergistically activated by the bg subunits of G proteins and phosphotyrosyl peptide. J. Biol. Chem. 272, 24252–24256 (1997).
  Article CAS PubMed Google Scholar
• Roche, S., Downward, J., Raynal, P. & Courtneidge, S. A. A function for phosphatidylinositol 3-kinase b (p85a–p110b) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. Mol. Cell Biol. 18, 7119–7129 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  Article CAS PubMed Google Scholar
• Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356–362 (1997). References 25 and 26 identifed PTEN as a candidate tumour suppressor gene.
  Article CAS PubMed Google Scholar
• Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 273, 13375–13378 (1998). This study showed that PTEN is a lipid phosphatase.
  Article CAS PubMed Google Scholar
• Maehama, T. & Dixon, J. E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9, 125–128 (1999).
  Article CAS PubMed Google Scholar
• Sansal, I. & Sellers, W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954–2963 (2004).
  Article CAS PubMed Google Scholar
• Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563–1568 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, e59 (2003).
  Article PubMed PubMed Central Google Scholar
• Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).
  Article CAS PubMed Google Scholar
• Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117–127 (2004).
  Article CAS PubMed Google Scholar
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (2004). This study reported the discovery that somatic mutations in PIK3CA are a common event in human cancers.
• Velho, S. et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8, 255 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Dunlap, J. et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res. Treat. 6 May 2009 (doi: 10.1007/s10549-009-0406-1).
• Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351–1356 (2008). This study showed that lung cancers that express oncogenic Kras are resistant to a dual PI3K–mTOR inhibitor in vivo , but they respond to a combination of a MEK inhibitor and a dual PI3K–mTOR inhibitor.
  Article CAS PubMed Google Scholar
• Yu, J., Wjasow, C. & Backer, J. M. Regulation of the p85/p110a phosphatidylinositol 3′-kinase. Distinct roles for the N-terminal and C-terminal SH2 domains. J. Biol. Chem. 273, 30199–30203 (1998).
  Article CAS PubMed Google Scholar
• Miled, N. et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239–242 (2007).
  Article CAS PubMed Google Scholar
• Huang, C. H. et al. The structure of a human p110a/p85a complex elucidates the effects of oncogenic PI3Ka mutations. Science 318, 1744–1748 (2007). References 39 and 40 provided the structural basis for the increased activity of PIK3CA mutants, particularly mutants in the helical domain of p110α.
  Article CAS PubMed Google Scholar
• Carson, J. D. et al. Effects of oncogenic p110a subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem. J. 409, 519–524 (2008).
  Article CAS PubMed Google Scholar
• Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652–2657 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
• Philp, A. J. et al. The phosphatidylinositol 3′-kinase p85a gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426–7429 (2001).
  CAS PubMed Google Scholar
• Shekar, S. C. et al. Mechanism of constitutive PI 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J. Biol. Chem. 280, 27850–27855 (2005).
  Article CAS PubMed Google Scholar
• Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439–444 (2007). This study identified and characterized the AKT1-E17K mutation associated with cancer.
  Article CAS PubMed Google Scholar
• Kim, M. S., Jeong, E. G., Yoo, N. J. & Lee, S. H. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98, 1533–1535 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Malanga, D. et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7, 665–669 (2008).
  Article CAS PubMed Google Scholar
• Davies, M. A. et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99, 1265–1268 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005).
  Article CAS PubMed Google Scholar
• Brugge, J., Hung, M. C. & Mills, G. B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12, 104–107 (2007).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Transient potent BCR–ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485–493 (2008).
  Article CAS PubMed Google Scholar
• Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110a subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963–10968 (1999).
  Article CAS PubMed Google Scholar
• Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI3-kinase. Mamm. Genome 13, 169–172 (2002).
  CAS PubMed Google Scholar
• Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase g in inflammation. Science 287, 1049–1053 (2000).
  Article CAS PubMed Google Scholar
• Sasaki, T. et al. Function of PI3Kg in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040–1046 (2000).
  Article CAS PubMed Google Scholar
• Clayton, E. et al. A crucial role for the p110d subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196, 753–763 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110d PI3-kinase mutant mice. Science 297, 1031–1034 (2002).
  CAS PubMed Google Scholar
• Jou, S. T. et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110d in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580–8591 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Jia, S. et al. Essential roles of PI(3)K–p110b in cell growth, metabolism and tumorigenesis. Nature 454, 776–779 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Wee, S. et al. PTEN-deficient cancers depend on PIK3CB. Proc. Natl Acad. Sci. USA 105, 13057–13062 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, Q. et al. Phosphoinositide 3-OH kinase p85a and p110b are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27, 4569–4579 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Patrucco, E. et al. PI3Kg modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375–387 (2004).
  Article CAS PubMed Google Scholar
• Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194–204 (2005).
  Article CAS PubMed Google Scholar
• Rychahou, P. G. et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc. Natl Acad. Sci. USA 105, 20315–20320 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Irie, H. Y. et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition. J. Cell. Biol. 171, 1023–1034 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Maroulakou, I. G., Oemler, W., Naber, S. P. & Tsichlis, P. N. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 67, 167–177 (2007).
  Article CAS PubMed Google Scholar
• Fasolo, A. & Sessa, C. mTOR inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 17, 1717–1734 (2008).
  Article CAS PubMed Google Scholar
• Rini, B. I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14, 1286–1290 (2008).
  Article CAS PubMed Google Scholar
• Easton, J. B. & Houghton, P. J. mTOR and cancer therapy. Oncogene 25, 6436–6446 (2006).
  Article CAS PubMed Google Scholar
• Abraham, R. T. & Gibbons, J. J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 13, 3109–3114 (2007).
  Article CAS PubMed Google Scholar
• Baldo, P. et al. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr. Cancer Drug Targets 8, 647–665 (2008).
  Article CAS PubMed Google Scholar
• O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500–1508 (2006). This study showed that mTORC1 signaling exerts a negative feedback on PI3K, and repression of PI3K activation is alleviated by rapamycin treatment.
  Article CAS PubMed PubMed Central Google Scholar
• Fan, Q. W. et al. A dual phosphoinositide-3-kinase a/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960–7965 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Graupera, M. et al. Angiogenesis selectively requires the p110a isoform of PI3K to control endothelial cell migration. Nature 453, 662–666 (2008).
  Article CAS PubMed Google Scholar
• Torbett, N. E. et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 415, 97–110 (2008).
  Article CAS PubMed Google Scholar
• Guerreiro, A. S. et al. Targeting the PI3K p110a isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin. Cancer Res. 14, 6761–6769 (2008).
  Article CAS PubMed Google Scholar
• Boller, D. et al. Targeting the phosphoinositide 3-kinase isoform p110d impairs growth and survival in neuroblastoma cells. Clin. Cancer Res. 14, 1172–1181 (2008).
  Article CAS PubMed Google Scholar
• Billottet, C., Banerjee, L., Vanhaesebroeck, B. & Khwaja, A. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res. 69, 1027–1036 (2009).
  Article CAS PubMed Google Scholar
• Sawyer, C. et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110d. Cancer Res 63, 1667–1675 (2003).
  CAS PubMed Google Scholar
• Sujobert, P. et al. Essential role for the p110d isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063–1066 (2005).
  Article CAS PubMed Google Scholar
• Billottet, C. et al. A selective inhibitor of the p110d isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648–6659 (2006).
  Article CAS PubMed Google Scholar
• Flinn, I. W. et al. Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J. Clin. Oncol. 27 (Suppl.), 3543 (2009).
  Google Scholar
• Stein, R. Prospects of phosphinositide 3-kinase inhibition as a cancer treatment. Endocrine Related Cancer 8, 237–248 (2001).
  Article CAS PubMed Google Scholar
• She, Q. B. et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3, e3065 (2008). This study showed that breast cancers with ERBB2 amplification or PIK3CA mutations are sensitive to Akt inhibitors.
  Article PubMed PubMed Central CAS Google Scholar
• Han, E. K. et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26, 5655–5661 (2007).
  Article CAS PubMed Google Scholar
• George, S. et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304, 1325–1328 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBb). Science 292, 1728–1731 (2001).
  Article CAS PubMed Google Scholar
• Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
  Article CAS PubMed Google Scholar
• Jacinto, E. et al. SIN1/MIP1 maintains rictor–mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125–137 (2006).
  Article CAS PubMed Google Scholar
• Serra, V. et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68, 8022–8030 (2008). This study showed that breast cancers with PIK3CA mutations are sensitive to dual PI3K–mTOR inhibitors.
  Article CAS PubMed Google Scholar
• Raynaud, F. I. et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840–5850 (2007).
  Article CAS PubMed Google Scholar
• Simi, L. et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol. 130, 247–253 (2008).
  Article CAS PubMed Google Scholar
• Ogino, S. et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 27, 1477–1484 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Eichhorn, P. J. et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221–9230 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J. A. et al. Allelic dilution obscures detection of a biologically significant resistance mutation in _EGFR_-amplified lung cancer. J. Clin. Invest. 116, 2695–2706 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ogino, A. et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 67, 7807–7814 (2007).
  Article CAS PubMed Google Scholar
• Yamasaki, F. et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 67, 5779–5788 (2007).
  Article CAS PubMed Google Scholar
• Ihle, N. T. et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69, 143–150 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gupta, S. et al. Binding of Ras to phosphoinositide 3-kinase p110a is required for Ras-driven tumorigenesis in mice. Cell 129, 957–968 (2007).
  Article CAS PubMed Google Scholar
• Yang, Y. et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic _K-ras_-induced lung cancer. PLoS ONE 3, e2220 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Schnell, C. R. et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 68, 6598–6607 (2008).
  Article CAS PubMed Google Scholar
• Yuan, T. L. et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc. Natl Acad. Sci. USA 105, 9739–9744 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article CAS PubMed Google Scholar
• Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hu, J. et al. Non-parametric quantification of protein lysate arrays. Bioinformatics 23, 1986–1994 (2007).
  Article CAS PubMed Google Scholar
• Cutillas, P. R. et al. Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc. Natl Acad. Sci. USA 103, 8959–8964 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Dowsett, M. et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer — a study from the IMPACT trialists. J. Clin. Oncol. 23, 2477–2492 (2005).
  Article CAS PubMed Google Scholar
• Guix, M. et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol. 26, 897–906 (2008).
  Article CAS PubMed Google Scholar
• Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366–377 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF1-dependent pathways. Nature Med. 10, 594–601 (2004).
  Article CAS PubMed Google Scholar
• Taniguchi, C. M. et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCl/z. Cell Metab. 3, 343–353 (2006).
  Article CAS PubMed Google Scholar
• Ihle, N. T. et al. Peroxisome proliferator-activated receptor g agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol. Cancer Ther. 8, 94–100 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065–3074 (2008).
  CAS PubMed PubMed Central Google Scholar
• She, Q. et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8, 287–297 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Zunder, E. R., Knight, Z. A., Houseman, B. T., Apsel, B. & Shokat, K. M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 a. Cancer Cell 14, 180–192 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science 307, 1098–1101 (2005). This study identified the mTOR–RICTOR complex as the kinase that phosphorylates Akt S473.
  Article CAS PubMed Google Scholar
• Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
  Article CAS PubMed Google Scholar
• Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).
  Article CAS PubMed Google Scholar
• Bader, A. G., Kang, S., Zhao, L. & Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nature Rev. Cancer 5, 921–929 (2005).
  Article CAS Google Scholar
• Manning, B. D. & Cantley, L. C. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 31, 573–578 (2003).
  Article CAS PubMed Google Scholar
• Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457–1466 (2003).
  Article CAS PubMed Google Scholar
• Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. & Blenis, J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259–1268 (2003).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nature Cell. Biol. 5, 578–581 (2003).
  Article CAS PubMed Google Scholar
• Inoki, K., Li, Y., Xu, T. & Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829–1834 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, J. & Manning, B. D. The TSC1–TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412, 179–190 (2008).
  Article CAS PubMed Google Scholar
• Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biol. 4, 648–657 (2002).
  Article CAS PubMed Google Scholar
• Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. & Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10, 151–162 (2002).
  Article CAS PubMed Google Scholar
• DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D. & Ellisen, L. W. Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239–251 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Nobukuni, T. et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl Acad. Sci. USA 102, 14238–14243 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Byfield, M. P., Murray, J. T. & Backer, J. M. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280, 33076–33082 (2005).
  Article CAS PubMed Google Scholar
• Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895–2899 (2008).
  Article PubMed Google Scholar
• Engelman, J. A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73–79 (2008).
  Article CAS PubMed Google Scholar
• Pedrero, J. M. et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114, 242–248 (2005).
  Article CAS PubMed Google Scholar
• Woenckhaus, J. et al. Genomic gain of PIK3CA and increased expression of p110a are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol. 198, 335–342 (2002).
  Article CAS PubMed Google Scholar
• Massion, P. P. et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 62, 3636–3640 (2002).
  CAS PubMed Google Scholar
• Bjorkqvist, A. M. et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 22, 79–82 (1998).
  Article CAS PubMed Google Scholar
• Ma, Y. Y. et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19, 2739–2744 (2000).
  Article CAS PubMed Google Scholar
• Byun, D. S. et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 104, 318–327 (2003).
  Article CAS PubMed Google Scholar
• Miller, C. T. et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin. Cancer Res. 9, 4819–4825 (2003).
  CAS PubMed Google Scholar
• Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl Acad. Sci. USA 84, 5034–5037 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Cheng, J. et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93, 3636–3641 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Ruggeri, B., Huang, L., Wood, M., Cheng, J. & Testa, J. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81–86 (1998).
  Article CAS PubMed Google Scholar
• Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995).
  Article CAS PubMed Google Scholar
• Maira, S. M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).
  Article CAS PubMed Google Scholar
• Garlich, J. R. et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 68, 206–215 (2008).
  Article CAS PubMed Google Scholar
• Ihle, N. T. et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3, 763–772 (2004).
  CAS PubMed Google Scholar
• Howes, A. L. et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 6, 2505–2514 (2007).
  Article CAS PubMed Google Scholar
• Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A. & Roy, K. K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2, 1093–1103 (2003).
  CAS PubMed Google Scholar
• Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053–4062 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Gills, J. J. & Dennis, P. A. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep. 11, 102–110 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hennessy, B. T. et al. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res. 13, 7421–7431 (2007).
  Article CAS PubMed Google Scholar
• Rhodes, N. et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366–2374 (2008).
  Article CAS PubMed Google Scholar
• Heerding, D. A. et al. Identification of 4-(2-(4-amino-1, 2, 5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]o xy}-1H imidazo[4, 5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. Med. Chem. 51, 5663–5679 (2008).
  Article CAS PubMed Google Scholar
• Vasudevan, K. M. et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21–32 (2009).
  Article CAS PubMed PubMed Central Google Scholar